| Literature DB >> 34203451 |
Christophe Vanhaver1, Pierre van der Bruggen1,2, Annika M Bruger1.
Abstract
Myeloid-derived suppressor cells (MDSCs) expand during pathological conditions in both humans and mice and their presence is linked to poor clinical outcomes for cancer patients. Studying MDSC immunosuppression is restricted by MDSCs' rarity, short lifespan, heterogeneity, poor viability after freezing and the lack of MDSC-specific markers. In this review, we will compare identification and isolation strategies for human and murine MDSCs. We will also assess what direct and indirect immunosuppressive mechanisms have been attributed to MDSCs. While some immunosuppressive mechanisms are well-documented in mice, e.g., generation of ROS, direct evidence is still lacking in humans. In future, bulk or single-cell genomics could elucidate which phenotypic and functional phenotypes MDSCs adopt in particular microenvironments and help to identify potential targets for therapy.Entities:
Keywords: MDSCs; T-cells; cancer biology; human; immunosuppressive assays; immunotherapy; mouse; myeloid-derived suppressor cells
Year: 2021 PMID: 34203451 DOI: 10.3390/jcm10132872
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241